MannKind MNKD Stock
MannKind Price Chart
MannKind MNKD Financial and Trading Overview
| MannKind stock price | 4.09 USD |
| Previous Close | 4.09 USD |
| Open | 4.04 USD |
| Bid | 2.96 USD x 200 |
| Ask | 5.1 USD x 200 |
| Day's Range | 3.95 - 4.14 USD |
| 52 Week Range | 2.23 - 6.51 USD |
| Volume | 4.04M USD |
| Avg. Volume | 5.69M USD |
| Market Cap | 1.25B USD |
| Beta (5Y Monthly) | 1.086 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.07 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.59 USD |
MNKD Valuation Measures
| Enterprise Value | 1.55B USD |
| Trailing P/E | N/A |
| Forward P/E | 20.987013 |
| PEG Ratio (5 yr expected) | 4.39 |
| Price/Sales (ttm) | 3.4595828 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 4.292 |
| Enterprise Value/EBITDA | 43.837 |
Trading Information
MannKind Stock Price History
| Beta (5Y Monthly) | 1.086 |
| 52-Week Change | 1.48% |
| S&P500 52-Week Change | 20.84% |
| 52 Week High | 6.51 USD |
| 52 Week Low | 2.23 USD |
| 50-Day Moving Average | 3.6 USD |
| 200-Day Moving Average | 4.44 USD |
MNKD Share Statistics
| Avg. Volume (3 month) | 5.69M USD |
| Avg. Daily Volume (10-Days) | 5.64M USD |
| Shares Outstanding | 308.95M |
| Float | 303.07M |
| Short Ratio | 4.97 |
| % Held by Insiders | 1.54% |
| % Held by Institutions | 59.24% |
| Shares Short | 26.19M |
| Short % of Float | 8.58% |
| Short % of Shares Outstanding | 8.48% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:5 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -6.62% |
| Operating Margin (ttm) | -3.30% |
| Gross Margin | 75.63% |
| EBITDA Margin | 9.79% |
Management Effectiveness
| Return on Assets (ttm) | 2.03% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 360.78M USD |
| Revenue Per Share (ttm) | 1.31 USD |
| Quarterly Revenue Growth (yoy) | 15.09% |
| Gross Profit (ttm) | 272.87M USD |
| EBITDA | 35.32M USD |
| Net Income Avi to Common (ttm) | -23914000 USD |
| Diluted EPS (ttm) | -0.07 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 133.86M USD |
| Total Cash Per Share (mrq) | 0.43 USD |
| Total Debt (mrq) | 434.15M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 1.867 |
| Book Value Per Share (mrq) | -0.192 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 19.27M USD |
| Levered Free Cash Flow (ttm) | 47M USD |
Profile of MannKind
| Country | United States |
| State | CT |
| City | Danbury |
| Address | 1 Casper Street |
| ZIP | 06810 |
| Phone | 818 661 5000 |
| Website | https://mannkindcorp.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 591 |
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Q&A For MannKind Stock
What is a current MNKD stock price?
MannKind MNKD stock price today per share is 4.09 USD.
How to purchase MannKind stock?
You can buy MNKD shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for MannKind?
The stock symbol or ticker of MannKind is MNKD.
Which industry does the MannKind company belong to?
The MannKind industry is Biotechnology.
How many shares does MannKind have in circulation?
The max supply of MannKind shares is 308.95M.
What is MannKind Price to Earnings Ratio (PE Ratio)?
MannKind PE Ratio is now.
What was MannKind earnings per share over the trailing 12 months (TTM)?
MannKind EPS is -0.07 USD over the trailing 12 months.
Which sector does the MannKind company belong to?
The MannKind sector is Healthcare.
MannKind MNKD included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26269.23 USD — |
+0.62
|
6.33B USD — | 26041.13 USD — | 26316.81 USD — | — - | 6.33B USD — |
|
Dow Jones U.S. Biotechnology In
DJUSBT
US
|
3236.38 USD — |
+0.3
|
74.33M USD — | 3218.19 USD — | 3258 USD — | — - | 74.33M USD — |
|
US Tech Composite Total Return
XCMP
US
|
32406.63 USD — |
+0.62
|
— — | 32125.24 USD — | 32465.34 USD — | — - | — — |
|
US Tech Global Market Composite
NQGM
US
|
2296.71 USD — |
-0.17
|
— — | 2271.37 USD — | 2311.92 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
|
US Tech Biotechnology Total Retu
XNBI
US
|
7161.62 USD — |
+0.7
|
— — | 7044.78 USD — | 7163.12 USD — | — - | — — |
|
US Tech US 700 Small Cap Index
NQUS700SC
US
|
3179.98 USD — |
+0.45
|
— — | 3165.92 USD — | 3192.38 USD — | — - | — — |
|
US Tech AlphaDEX Multi Cap Growt
NQDXUSMLTCG
US
|
4030.44 USD — |
-0.31
|
— — | 3987.18 USD — | 4063.78 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6562.03 USD — |
+0.7
|
— — | 6454.97 USD — | 6563.4 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1251.97 USD — |
+0.86
|
— — | 1233.72 USD — | 1252.49 USD — | — - | — — |
- {{ link.label }} {{link}}